Please use this identifier to cite or link to this item:
Title: Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
Authors: Tim R. Cressey
Plipat Nottasorn
Federica Fregonese
Kulkanya Chokephaibulkit
Keywords: Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Jun-2007
Abstract: For over a decade, indinavir has been approved for the treatment of HIV/ AIDS; however, following the introduction of new protease inhibitors (PIs) with improved safety and pharmacologic profiles, its use in developed countries has become almost obsolete. In contrast, in resource-limited settings where the majority of people living with HIV/ AIDS reside, indinavir is part of the most affordable PI-based highly active antiretroviral treatment regimen. A major drawback of indinavir use is renal toxicity, but low-dose indinavir plus ritonavir (400/100 mg) twice daily is both efficacious and tolerable. Similar low dosing levels in children have also proven successful, but data in pregnant women remains limited. Due to its low cost and proven efficacy indinavir remains a key component of HIV/AIDS treatment in resource-limited settings. © 2007 Informa UK Ltd.
ISSN: 17425255
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.